Equities research analysts predict that Catalent Inc (NYSE:CTLT) will announce earnings of $0.65 per share for the current fiscal quarter, Zacks Investment Research reports. Six analysts have provided estimates for Catalent’s earnings. The lowest EPS estimate is $0.62 and the highest is $0.66. Catalent reported earnings per share of $0.28 in the same quarter last year, which suggests a positive year-over-year growth rate of 132.1%. The business is expected to announce its next quarterly earnings report on Tuesday, November 5th.
On average, analysts expect that Catalent will report full year earnings of $1.98 per share for the current year, with EPS estimates ranging from $1.92 to $2.00. For the next financial year, analysts anticipate that the firm will post earnings of $2.24 per share, with EPS estimates ranging from $2.18 to $2.31. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Catalent.
Catalent (NYSE:CTLT) last issued its earnings results on Tuesday, August 27th. The company reported $0.65 EPS for the quarter, beating the consensus estimate of $0.62 by $0.03. Catalent had a return on equity of 15.89% and a net margin of 5.46%. The business had revenue of $725.70 million for the quarter, compared to the consensus estimate of $719.20 million. During the same period last year, the business posted $0.67 EPS. The company’s revenue was up 5.9% compared to the same quarter last year.
CTLT has been the topic of several recent analyst reports. Robert W. Baird increased their target price on Catalent from $50.00 to $60.00 and gave the company an “outperform” rating in a research note on Wednesday, August 28th. Jefferies Financial Group upgraded Catalent from a “hold” rating to a “buy” rating and increased their target price for the company from $50.00 to $62.00 in a research note on Friday, June 21st. Morgan Stanley increased their target price on Catalent from $50.00 to $61.00 and gave the company an “overweight” rating in a research note on Wednesday, August 28th. Zacks Investment Research downgraded Catalent from a “buy” rating to a “hold” rating in a research note on Monday. Finally, UBS Group increased their target price on Catalent to $64.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $57.00.
In other news, SVP Steven L. Fasman sold 4,053 shares of the stock in a transaction on Thursday, July 11th. The stock was sold at an average price of $54.04, for a total transaction of $219,024.12. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Gregory T. Lucier purchased 2,000 shares of the stock in a transaction dated Monday, September 9th. The shares were purchased at an average cost of $51.64 per share, for a total transaction of $103,280.00. The disclosure for this purchase can be found here. 1.30% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Evolution Wealth Advisors LLC bought a new position in shares of Catalent during the 2nd quarter valued at $32,000. Advisory Services Network LLC lifted its holdings in shares of Catalent by 115.5% during the 2nd quarter. Advisory Services Network LLC now owns 737 shares of the company’s stock valued at $39,000 after buying an additional 395 shares during the period. Bremer Bank National Association bought a new position in shares of Catalent during the 1st quarter valued at $49,000. Bamco Inc. NY bought a new position in Catalent in the 2nd quarter worth $81,000. Finally, Zions Bancorporation N.A. bought a new position in Catalent in the 1st quarter worth $61,000.
CTLT traded up $0.21 during trading on Monday, hitting $47.66. 712,413 shares of the company’s stock traded hands, compared to its average volume of 826,126. The company’s 50 day simple moving average is $52.53 and its two-hundred day simple moving average is $49.06. The company has a current ratio of 2.08, a quick ratio of 1.70 and a debt-to-equity ratio of 1.71. Catalent has a 12-month low of $29.23 and a 12-month high of $58.38. The stock has a market capitalization of $7.10 billion, a price-to-earnings ratio of 29.42, a PEG ratio of 2.39 and a beta of 1.65.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
See Also: Diversification
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.